MicroRNA regulatory networks in idiopathic pulmonary fibrosis1

Biochemistry and Cell Biology

Volumn 93, Issue 2, 2015, Pages 129-137

  Pandit, Kusum V ^a   Milosevic, Jadranka ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Epithelial mesenchymal transition; Fibroblasts; IPF; MicroRNA; TGF

Indexed keywords

ALKYLATION; CELL CULTURE; FIBROBLASTS; PULMONARY DISEASES;

EPIGENETIC MODIFICATION; EPIGENETIC REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; IDIOPATHIC PULMONARY FIBROSIS; IPF; MICRORNA EXPRESSION; MICRORNAS; TRANSFORMING GROWTH FACTORS;

RNA;

ANTAGOMIR; MICRORNA; MICRORNA 122; MICRORNA 145; MICRORNA 154; MICRORNA 199A 5P; MICRORNA 200; MICRORNA 21; MICRORNA 26A; MICRORNA 29; MICRORNA 326; MICRORNA 34; MICRORNA LET 7D; MIRAVIRSEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CELL CULTURE; CHEMICAL MODIFICATION; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FIBROBLAST; FIBROSING ALVEOLITIS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA METHYLATION;

ANIMALS; CELLS, CULTURED; DNA METHYLATION; EPIGENESIS, GENETIC; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; GENE EXPRESSION REGULATION; GENETICS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; METABOLISM; MICE; MICRORNAS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84964296861     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/bcb-2014-0101     Document Type: Article

References (101)

1. Andersson-Sjoland A. de Alba C.G. Nihlberg K. Becerril C. Ramirez R. Pardo A. et al 2008. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. 40 (10): 2129-2140. 10.1016/j.biocel.2008.02.012. 18374622.
2. Bartis D. Mise N. Mahida R.Y. Eickelberg O. Thickett D.R. 2014. Epithelial-mesenchymal transition in lung development and disease: does it exist and is it important? Thorax. 69 (8): 760-765. 10.1136/thoraxjnl-2013-204608.
3. Boon K. Bailey N.W. Yang J. Steel M.P. Groshong S. Kervitsky D. et al 2009. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One, 4 (4): e5134. 10.1371/journal.pone.0005134. 19347046.
4. Chapman H.A. 2004. Disorders of lung matrix remodeling. J. Clin. Invest. 113 (2): 148-157. 10.1172/JCI200420729, 10.1172/JCI20729. 14722604.
5. Chapman H.A. 2011. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu. Rev. Physiol. 73: 413-435. 10.1146/annurev-physiol-012110-142225. 21054168.
6. Cho J.H. Gelinas R. Wang K. Etheridge A. Piper M.G. Batte K. et al 2011. Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes. BMC Med. Genomics, 4: 8. 10.1186/1755-8794-4-8. 21241464.
7. Lung Genomics Research Consortium. 2010. Available from http://www.lung-genomics.org.
8. Crawford S.E. Stellmach V. Murphy-Ullrich J.E. Ribeiro S.M. Lawler J. Hynes R.O. et al 1998. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell, 93 (7): 1159-1170. 10.1016/S0092-8674(00)81460-9. 9657149.
9. Cushing L. Kuang P.P. Qian J. Shao F. Wu J. Little F. et al 2011. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 45 (2): 287-294. 10.1165/rcmb.2010-0323OC. 20971881.
10. Dakhlallah D. Batte K. Wang Y. Cantemir-Stone C.Z. Yan P. Nuovo G. et al 2013. Epigenetic regulation of miR-17-92 contributes to the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 187 (4): 397-405. 10.1164/rccm.201205-0888OC. 23306545.
11. Dancer R.C. Wood A.M. Thickett D.R. 2011. Metalloproteinases in idiopathic pulmonary fibrosis. Eur. Respir. J. 38 (6): 1461-1467. 10.1183/09031936.00024711. 21700608.
12. Das S. Kumar M. Negi V. Pattnaik B. Prakash Y.S. Agrawal A. Ghosh B. 2014. MicroRNA-326 regulates profibrotic functions of transforming growth factor-beta in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 50 (5): 882-892. 10.1165/rcmb.2013-0195OC. 24279830.
13. Diaz-Martin J. Diaz-Lopez A. Moreno-Bueno G. Castilla M.A. Rosa-Rosa J.M. Cano A. Palacios J. 2014. A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. J. Pathol. 232 (3): 319-329. 10.1002/path.4289. 24122292.
14. du Bois R.M. 2010. Strategies for treating idiopathic pulmonary fibrosis. Nat. Rev. Drug Discov. 9 (2): 129-140. 10.1038/nrd2958. 20094055.
15. Esquela-Kerscher A. Trang P. Wiggins J.F. Patrawala L. Cheng A. Ford L. et al 2008. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle, 7 (6): 759-764. 10.4161/cc.7.6.5834. 18344688.
16. Fabbri M. Garzon R. Cimmino A. Liu Z. Zanesi N. Callegari E. et al 2007. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U.S.A. 104 (40): 15805-15810. 10.1073/pnas.0707628104. 17890317.
17. Fattman C.L. 2008. Apoptosis in pulmonary fibrosis: too much or not enough? Antioxid. Redox Signal. 10 (2): 379-385. 10.1089/ars.2007.1907. 18031201.
18. Fernandes D.J. Bonacci J.V. Stewart A.G. 2006. Extracellular matrix, integrins, and mesenchymal cell function in the airways. Curr. Drug Targets, 7 (5): 567-577. 10.2174/138945006776818700. 16719767.
19. Fernandez I.E. Eickelberg O. 2012. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc. Am. Thorac. Soc. 9 (3): 111-116. 10.1513/pats.201203-023AW. 22802283.
20. Friedman R.C. Farh K.K. Burge C.B. Bartel D.P. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19 (1): 92-105. 10.1101/gr.082701.108. 18955434.
21. Garzon R. Liu S. Fabbri M. Liu Z. Heaphy C.E. Callegari E. et al 2009. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 113 (25): 6411-6418. 10.1182/blood-2008-07-170589. 19211935.
22. Gaudet F. Hodgson J.G. Eden A. Jackson-Grusby L. Dausman J. Gray J.W. et al 2003. Induction of tumors in mice by genomic hypomethylation. Science, 300 (5618): 489-492. 10.1126/science.1083558. 12702876.
23. Gregory P.A. Bert A.G. Paterson E.L. Barry S.C. Tsykin A. Farshid G. et al 2008. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10 (5): 593-601. 10.1038/ncb1722. 18376396.
24. Gross T.J. Hunninghake G.W. 2001. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345 (7): 517-525. 10.1056/NEJMra003200. 11519507.
25. He L. He X. Lim L.P. de Stanchina E. Xuan Z. Liang Y. et al 2007. A microRNA component of the p53 tumour suppressor network. Nature, 447 (7148): 1130-1134. 10.1038/nature05939. 17554337.
26. Hecker L. Vittal R. Jones T. Jagirdar R. Luckhardt T.R. Horowitz J.C. et al 2009. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 15 (9): 1077-1081. 10.1038/nm.2005. 19701206.
27. Hinz B. Phan S.H. Thannickal V.J. Galli A. Bochaton-Piallat M.L. Gabbiani G. 2007. The myofibroblast: one function, multiple origins. Am. J. Pathol. 170 (6): 1807-1816. 10.2353/ajpath.2007.070112. 17525249.
28. Hinz B. Phan S.H. Thannickal V.J. Prunotto M. Desmouliere A. Varga J. et al 2012. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 180 (4): 1340-1355. 10.1016/j.ajpath.2012.02.004. 22387320.
29. Huleihel L. Ben-Yehudah A. Milosevic J. Yu G. Pandit K. Sakamoto K. et al 2014. Let-7d microRNA affects mesenchymal phenotypic properties of lung fibroblasts. Am. J. Physiol. Lung Cell. Mol. Physiol. 306 (6): L534-L542. 10.1152/ajplung.00149.2013. 24441869.
30. Hwang H.W. Mendell J.T. 2006. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br. J. Cancer, 94 (6): 776-780. 10.1038/sj.bjc.6603023. 16495913.
31. Janssen H.L. Reesink H.W. Lawitz E.J. Zeuzem S. Rodriguez-Torres M. Patel K. et al 2013. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368 (18): 1685-1694. 10.1056/NEJMoa1209026. 23534542.
32. Johnson C.D. Esquela-Kerscher A. Stefani G. Byrom M. Kelnar K. Ovcharenko D. et al 2007. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 67 (16): 7713-7722. 10.1158/0008-5472.CAN-07-1083. 17699775.
33. Jovanovic M. Reiter L. Picotti P. Lange V. Bogan E. Hurschler B.A. et al 2010. A quantitative targeted proteomics approach to validate predicted microRNA targets in C. elegans. Nat. Methods, 7 (10): 837-842. 10.1038/nmeth.1504. 20835247.
34. Kage H. Borok Z. 2012. EMT and interstitial lung disease: a mysterious relationship. Curr. Opin. Pulm. Med. 18 (5): 517-523. 10.1097/MCP.0b013e3283566721. 22854509.
35. Kalluri R. 2009. EMT: when epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 119: 1417-1419. 10.1172/JCI39675.
36. Kendall R.T. Feghali-Bostwick C.A. 2014. Fibroblasts in fibrosis: novel roles and mediators. Front. Pharmacol. 5: 123. 10.3389/fphar.2014.00123. 24904424.
37. Kim K.K. Kugler M.C. Wolters P.J. Robillard L. Galvez M.G. Brumwell A.N. et al 2006. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. U.S.A. 103 (35): 13180-13185. 10.1073/pnas.0605669103. 16924102.
38. Kim K.K. Wei Y. Szekeres C. Kugler M.C. Wolters P.J. Hill M.L. et al 2009. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J. Clin. Invest. 119 (1): 213-224. 10.1172/JCI36940. 19104148.
39. King T.E. Jr. Pardo A. Selman M. 2011. Idiopathic pulmonary fibrosis. Lancet, 378 (9807): 1949-1961. 10.1016/S0140-6736(11)60052-4. 21719092.
40. Kishikawa S. Murata T. Kimura H. Shiota K. Yokoyama K.K. 2002. Regulation of transcription of the Dnmt1 gene by Sp1 and Sp3 zinc finger proteins. Eur. J. Biochem. 269 (12): 2961-2970. 10.1046/j.1432-1033.2002.02972.x. 12071960.
41. Konishi K. Gibson K.F. Lindell K.O. Richards T.J. Zhang Y. Dhir R. et al 2009. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 180 (2): 167-175. 10.1164/rccm.200810-1596OC. 19363140.
42. Korfei M. Schmitt S. Ruppert C. Henneke I. Markart P. Loeh B. et al 2011. Comparative proteomic analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and lung transplant donor lungs. J. Proteome Res. 10 (5): 2185-2205. 10.1021/pr1009355. 21319792.
43. Korfei M. von der Beck D. Henneke I. Markart P. Ruppert C. Mahavadi P. et al 2013. Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. J. Proteomics, 85: 109-128. 10.1016/j.jprot.2013.04.033. 23659799.
44. Krutzfeldt J. Rajewsky N. Braich R. Rajeev K.G. Tuschl T. Manoharan M. Stoffel M. 2005. Silencing of microRNAs in vivo with antagomirs. Nature, 438 (7068): 685-689. 10.1038/nature04303. 16258535.
45. Kumar M.S. Erkeland S.J. Pester R.E. Chen C.Y. Ebert M.S. Sharp P.A. Jacks T. 2008. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. U.S.A. 105 (10): 3903-3908. 10.1073/pnas.0712321105. 18308936.
46. Lamouille S. Xu J. Derynck R. 2014. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15 (3): 178-196. 10.1038/nrm3758. 24556840.
47. Lanford R.E. Hildebrandt-Eriksen E.S. Petri A. Persson R. Lindow M. Munk M.E. et al 2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science, 327 (5962): 198-201. 10.1126/science.1178178. 19965718.
48. Lau N.C. Lai E.C. 2005. Diverse roles for RNA in gene regulation. Genome Biol. 6 (4): 315. 10.1186/gb-2005-6-4-315. 15833133.
49. Lau N.C. Lim L.P. Weinstein E.G. Bartel D.P. 2001. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science, 294 (5543): 858-862. 10.1126/science.1065062. 11679671.
50. Liang H. Gu Y. Li T. Zhang Y. Huangfu L. Hu M. et al 2014 a. Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis. Cell Death Dis. 5: e1238. 10.1038/cddis.2014.207. 24853416.
51. Liang H. Xu C. Pan Z. Zhang Y. Xu Z. Chen Y. et al 2014 b. The Antifibrotic Effects and Mechanisms of MicroRNA-26a Action in Idiopathic Pulmonary Fibrosis. Mol. Ther. 22 (6): 1122-1133. 24594795.
52. Ling H. Fabbri M. Calin G.A. 2013. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12 (11): 847-865. 10.1038/nrd4140. 24172333.
53. Lino Cardenas C.L. Henaoui I.S. Courcot E. Roderburg C. Cauffiez C. Aubert S. et al 2013. miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1. PLoS Genet. 9 (2): e1003291. 10.1371/journal.pgen.1003291. 23459460.
54. Liu G. Friggeri A. Yang Y. Milosevic J. Ding Q. Thannickal V.J. et al 2010. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 207 (8): 1589-1597. 10.1084/jem.20100035. 20643828.
55. Liu Y. Sinha S. Owens G. 2003. A transforming growth factor-beta control element required for SM alpha-actin expression in vivo also partially mediates GKLF-dependent transcriptional repression. J. Biol. Chem. 278 (48): 48004-48011. 10.1074/jbc.M301902200. 12970361.
56. Liu Y.N. Yin J.J. Abou-Kheir W. Hynes P.G. Casey O.M. Fang L. et al 2013. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene, 32 (3): 296-306. 10.1038/onc.2012.58. 22370643.
57. Ma L. Young J. Prabhala H. Pan E. Mestdagh P. Muth D. et al 2010. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12 (3): 247-256. 10.1038/ncb2024. 20173740.
58. Margadant C. Sonnenberg A. 2010. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 11 (2): 97-105. 10.1038/embor.2009.276. 20075988.
59. Mayr C. Hemann M.T. Bartel D.P. 2007. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science, 315: 1576-1579. 10.1126/science.1137999.
60. Milosevic J. Pandit K. Magister M. Rabinovich E. Ellwanger D.C. Yu G. et al 2012. Profibrotic role of miR-154 in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 47 (6): 879-887. 10.1165/rcmb.2011-0377OC. 23043088.
61. Moeller A. Gilpin S.E. Ask K. Cox G. Cook D. Gauldie J. et al 2009. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179 (7): 588-594. 10.1164/rccm.200810-1534OC. 19151190.
62. Pandit K.V. Corcoran D. Yousef H. Yarlagadda M. Tzouvelekis A. Gibson K.F. et al 2010. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 182 (2): 220-229. 10.1164/rccm.200911-1698OC. 20395557.
63. Pandit K.V. Milosevic J. Kaminski N. 2011 a. MicroRNAs in idiopathic pulmonary fibrosis. Transl. Res. 157 (4): 191-199. 10.1016/j.trsl.2011.01.012. 21420029.
64. Pandit K. Milosevic J. Benos P. Coronello C. Ben-Yehudah A. Hagood J. et al 2011 b. Global Microrna Profiles Of Idiopathic Pulmonary Fibrosis Lungs Indicate Reversal Of Lung Differentiation. Am. J. Respir. Crit. Care Med. 183: A5528.
65. Pardo A. Selman M. 2006. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc. Am. Thorac. Soc. 3 (4): 383-388. 10.1513/pats.200601-012TK. 16738205.
66. Parker M.W. Rossi D. Peterson M. Smith K. Sikstrom K. White E.S. et al 2014. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J. Clin. Invest. 124 (4): 1622-1635. 10.1172/JCI71386. 24590289.
67. Rabinovich E.I. Kapetanaki M.G. Steinfeld I. Gibson K.F. Pandit K.V. Yu G. et al 2012 a. Global methylation patterns in idiopathic pulmonary fibrosis. PLoS One, 7 (4): e33770. 10.1371/journal.pone.0033770. 22506007.
68. Rabinovich E.I. Selman M. Kaminski N. 2012 b. Epigenomics of idiopathic pulmonary fibrosis: evaluating the first steps. Am J. Respir. Crit. Care Med. 186 (6): 473-475. 10.1164/rccm.201208-1350ED. 22984022.
69. Raghu G. Collard H.R. Egan J.J. Martinez F.J. Behr J. Brown K.K. et al 2011. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183 (6): 788-824. 10.1164/rccm.2009-040GL. 21471066.
70. Raj K. Mufti G.J. 2006. Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes. Ther. Clin. Risk Manag. 2 (4): 377-388. 10.2147/tcrm.2006.2.4.377. 18360650.
71. Rock J.R. Barkauskas C.E. Cronce M.J. Xue Y. Harris J.R. Liang J. et al 2011. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl. Acad. Sci. U.S.A. 108 (52): E1475-E1483. 10.1073/pnas.1117988108. 22123957.
72. Ru P. Steele R. Newhall P. Phillips N.J. Toth K. Ray R.B. 2012. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol. Cancer Ther. 11 (5): 1166-1173. 10.1158/1535-7163.MCT-12-0100. 22402125.
73. Sanders Y.Y. Ambalavanan N. Halloran B. Zhang X. Liu H. Crossman D.K. et al 2012. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 186 (6): 525-535. 10.1164/rccm.201201-0077OC. 22700861.
74. Schiller H.B. Fernandez I.E. Burgstaller G. Staab-Weijnitz C.A. Mann M. Eickelberg O. 2014. Quantitative Proteomic Profiling Of Extracellular Matrix Composition And Protein Secretion Reveals Novel Modulators Of Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 189: A3652.
75. Scotton C.J. Krupiczojc M.A. Konigshoff M. Mercer P.F. Lee Y.C. Kaminski N. et al 2009. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J. Clin. Invest. 119 (9): 2550-2563. 10.1172/JCI33288. 19652365.
76. Selman M. Pardo A. Barrera L. Estrada A. Watson S.R. Wilson K. et al 2006. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 173 (2): 188-198. 10.1164/rccm.200504-644OC. 16166619.
77. Selman M. Carrillo G. Estrada A. Mejia M. Becerril C. Cisneros J. et al 2007. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One, 2 (5): e482. 10.1371/journal.pone.0000482. 17534432.
78. Selman M. Pardo A. Kaminski N. 2008. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med. 5 (3): e62. 10.1371/journal.pmed.0050062. 18318599.
79. Sheppard D. 2006. Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc. Am. Thorac. Soc. 3 (5): 413-417. 10.1513/pats.200601-008AW. 16799084.
80. Shi Y. Gochuico B.R. Yu G. Tang X. Osorio J.C. Fernandez I.E. et al 2013. Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-beta receptor I internalization and inhibiting transforming growth factor-beta1 signaling. Am. J. Respir. Crit. Care Med. 188 (7): 831-841. 10.1164/rccm.201303-0434OC. 23924348.
81. Strieter R.M. Mehrad B. 2009. New mechanisms of pulmonary fibrosis. Chest, 136 (5): 1364-1370. 10.1378/chest.09-0510. 19892675.
82. TargetScan. 2012. TargetScan version 6.2. Available from http://www.targetscan.org.
83. Thannickal V.J. Horowitz J.C. 2006. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 3 (4): 350-356. 10.1513/pats.200601-001TK. 16738200.
84. Thuault S. Valcourt U. Petersen M. Manfioletti G. Heldin C.H. Moustakas A. 2006. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J. Cell Biol. 174 (2): 175-183. 10.1083/jcb.200512110. 16831886.
85. Thuault S. Tan E.J. Peinado H. Cano A. Heldin C.H. Moustakas A. 2008. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J. Biol. Chem. 283 (48): 33437-33446. 10.1074/jbc.M802016200. 18832382.
86. Trang P. Wiggins J.F. Daige C.L. Cho C. Omotola M. Brown D. et al 2011. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19 (6): 1116-1122. 10.1038/mt.2011.48. 21427705.
87. van Rooij E. Sutherland L.B. Thatcher J.E. DiMaio J.M. Naseem R.H. Marshall W.S. et al 2008. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U.S.A. 105 (35): 13027-13032. 10.1073/pnas.0805038105. 18723672.
88. Ventura A. Young A.G. Winslow M.M. Lintault L. Meissner A. Erkeland S.J. et al 2008. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell, 132 (5): 875-886. 10.1016/j.cell.2008.02.019. 18329372.
89. Vuga L.J. Ben-Yehudah A. Kovkarova-Naumovski E. Oriss T. Gibson K.F. Feghali-Bostwick C. Kaminski N. 2009. WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis. Am. J. Respir. Cell Mol. Biol. 41 (5): 583-589. 10.1165/rcmb.2008-0201OC. 19251946.
90. Wang X.J. Reyes J.L. Chua N.H. Gaasterland T. 2004. Prediction and identification of Arabidopsis thaliana microRNAs and their mRNA targets. Genome Biol. 5 (9): R65. 10.1186/gb-2004-5-9-r65. 15345049.
91. Wang X.M. Zhang Y. Kim H.P. Zhou Z. Feghali-Bostwick C.A. Liu F. et al 2006. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J. Exp. Med. 203 (13): 2895-2906. 10.1084/jem.20061536. 17178917.
92. Wei C. Kim I.K. Kumar S. Jayasinghe S. Hong N. Castoldi G. et al 2013. NF-kappaB mediated miR-26a regulation in cardiac fibrosis. J. Cell. Physiol. 228 (7): 1433-1442. 10.1002/jcp.24296. 23254997.
93. Willis B.C. Borok Z. 2007. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am. J. Physiol. 293 (3): L525-L534. 10.1152/ajplung.00163.2007. 17631612.
94. Wipff P.J. Rifkin D.B. Meister J.J. Hinz B. 2007. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J. Cell Biol. 179 (6): 1311-1323. 10.1083/jcb.200704042. 18086923.
95. Wu Y. Crawford M. Yu B. Mao Y. Nana-Sinkam S.P. Lee L.J. 2011. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol. Pharm. 8 (4): 1381-1389. 10.1021/mp2002076. 21648427.
96. Xiao J. Meng X.M. Huang X.R. Chung A.C. Feng Y.L. Hui D.S. et al 2012. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol. Ther. 20 (6): 1251-1260. 10.1038/mt.2012.36. 22395530.
97. Yang I.V. Burch L.H. Steele M.P. Savov J.D. Hollingsworth J.W. McElvania-Tekippe E. et al 2007. Gene expression profiling of familial and sporadic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 175 (1): 45-54. 10.1164/rccm.200601-062OC. 16998095.
98. Yang S. Banerjee S. de Freitas A. Sanders Y.Y. Ding Q. Matalon S. et al 2012. Participation of miR-200 in pulmonary fibrosis. Am. J. Pathol. 180 (2): 484-493. 10.1016/j.ajpath.2011.10.005. 22189082.
99. Yang S. Cui H. Xie N. Icyuz M. Banerjee S. Antony V.B. et al 2013. miR-145 regulates myofibroblast differentiation and lung fibrosis. FASEB J. 27 (6): 2382-2391. 10.1096/fj.12-219493. 23457217.
100. Yates L.A. Norbury C.J. Gilbert R.J. 2013. The long and short of microRNA. Cell, 153 (3): 516-519. 10.1016/j.cell.2013.04.003. 23622238.
101. Zuo F. Kaminski N. Eugui E. Allard J. Yakhini Z. Ben-Dor A. et al 2002. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6292-6297. 10.1073/pnas.092134099. 11983918.